Effect of cimetidine on gastrointestinal symptoms in patients taking nonsteroidal anti-inflammatory drugs. A large double-blind placebo controlled study
- PMID: 8091142
- DOI: 10.3109/03009749409103057
Effect of cimetidine on gastrointestinal symptoms in patients taking nonsteroidal anti-inflammatory drugs. A large double-blind placebo controlled study
Abstract
The effect of cimetidine on gastrointestinal (GI) symptoms in patients taking non-steroidal anti-inflammatory drugs was studied in a multicentre, double-blind, placebo-controlled 4 week trial. Five hundred and seventy osteoarthritis patients received cimetidine 400 mg bid or placebo. Seventy-nine % in the cimetidine group had no GI symptoms at week 4 compared to 72% in the placebo group (p = 0.07). Only 5.6% in the cimetidine group reported heartburn compared to 19.2% in the placebo group. Diarrhoea was more pronounced in cimetidine treated patients; 18.5% compared to 2.7%. In a subgroup of patients with previous GI discomfort on NSAID therapy (N = 123), 63% reported disappearance of symptoms in the cimetidine group compared to 45% in the placebo group (p = 0.05). In patients with GI symptoms starting NSAID therapy and in patients on NSAID with a heartburn problem, cimetidine seems to be of value.
Similar articles
-
Treatment of endoscopy-negative NSAID-induced upper gastrointestinal symptoms with cimetidine: an international multicentre collaborative study.Aliment Pharmacol Ther. 1988;2 Suppl 1:75-83. doi: 10.1111/j.1365-2036.1988.tb00767.x. Aliment Pharmacol Ther. 1988. PMID: 2979286 Clinical Trial.
-
Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluation.Arch Intern Med. 1987 Oct;147(10):1798-801. Arch Intern Med. 1987. PMID: 3310942 Clinical Trial.
-
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247. JAMA. 2000. PMID: 10979111 Clinical Trial.
-
Epidemiology of NSAID-induced gastrointestinal problems and the role of cimetidine in their prevention.Aliment Pharmacol Ther. 1988;2 Suppl 1:33-41. doi: 10.1111/j.1365-2036.1988.tb00763.x. Aliment Pharmacol Ther. 1988. PMID: 2979283 Review.
-
The role of H2-receptor antagonists in the prevention of NSAID-induced gastrointestinal damage.Aliment Pharmacol Ther. 1988;2 Suppl 1:65-73. doi: 10.1111/j.1365-2036.1988.tb00766.x. Aliment Pharmacol Ther. 1988. PMID: 2908758 Review.
Cited by
-
An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada.Pharmacoeconomics. 2001;19 Suppl 1:49-58. doi: 10.2165/00019053-200119001-00004. Pharmacoeconomics. 2001. PMID: 11280105
-
Prevention of chronic NSAID induced upper gastrointestinal toxicity.Cochrane Database Syst Rev. 2000;2002(3):CD002296. doi: 10.1002/14651858.CD002296. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2000;(4):CD002296. doi: 10.1002/14651858.CD002296. PMID: 10908548 Free PMC article. Updated.
-
A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis.Pharmacoeconomics. 2001;19 Suppl 1:33-47. doi: 10.2165/00019053-200119001-00003. Pharmacoeconomics. 2001. PMID: 11280104 Review.
-
Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.Pharmacoeconomics. 2001;19 Suppl 1:59-75. doi: 10.2165/00019053-200119001-00005. Pharmacoeconomics. 2001. PMID: 11280106
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical